RC

AVITA Medical IncNASDAQ RCEL Stock Report

Last reporting period 30 Sep, 2024

Updated 18 Nov, 2024

Last price

Market cap $B

0.275

Micro

Exchange

XNAS - Nasdaq

RCEL Stock Analysis

RC

Uncovered

AVITA Medical Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-35/100

Low score

Market cap $B

0.275

Dividend yield

Shares outstanding

24.843 B

AVITA Medical, Inc. through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California. The company went IPO on 2012-03-18. The firm is focused on the development and commercialization of devices and autologous cellular therapies for skin restoration. The company provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The company offers RECELL System technology platform for the treatment of acute thermal burns in both adults and children. The RECELL System is used to prepare Spray-On Skin Cells using patient’s own skin to treat severe burns, while reducing the amount of donor skin required.

View Section: Eyestock Rating